These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24552952)

  • 21. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.
    Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W
    Front Immunol; 2021; 12():655743. PubMed ID: 33868299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine.
    Partidos CD; Paykel J; Weger J; Borland EM; Powers AM; Seymour R; Weaver SC; Stinchcomb DT; Osorio JE
    Vaccine; 2012 Jun; 30(31):4638-43. PubMed ID: 22583812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
    Weber C; Büchner SM; Schnierle BS
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003684. PubMed ID: 25905779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
    Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
    Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling.
    Partidos CD; Weger J; Brewoo J; Seymour R; Borland EM; Ledermann JP; Powers AM; Weaver SC; Stinchcomb DT; Osorio JE
    Vaccine; 2011 Apr; 29(16):3067-73. PubMed ID: 21300099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High level of vector competence of Aedes aegypti and Aedes albopictus from ten American countries as a crucial factor in the spread of Chikungunya virus.
    Vega-Rúa A; Zouache K; Girod R; Failloux AB; Lourenço-de-Oliveira R
    J Virol; 2014 Jun; 88(11):6294-306. PubMed ID: 24672026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of Vaccines for Chikungunya Fever.
    Erasmus JH; Rossi SL; Weaver SC
    J Infect Dis; 2016 Dec; 214(suppl 5):S488-S496. PubMed ID: 27920179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
    Chattopadhyay A; Wang E; Seymour R; Weaver SC; Rose JK
    J Virol; 2013 Jan; 87(1):395-402. PubMed ID: 23077320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort.
    Yoon IK; Srikiatkhachorn A; Alera MT; Fernandez S; Cummings DAT; Salje H
    Int J Infect Dis; 2020 Jun; 95():167-173. PubMed ID: 32247051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme-linked immunosorbent assay using recombinant envelope protein 2 antigen for diagnosis of Chikungunya virus.
    Fumagalli MJ; de Souza WM; Espósito DLA; Silva A; Romeiro MF; Martinez EZ; da Fonseca BAL; Figueiredo LTM
    Virol J; 2018 Jul; 15(1):112. PubMed ID: 30041676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
    Warter L; Lee CY; Thiagarajan R; Grandadam M; Lebecque S; Lin RT; Bertin-Maghit S; Ng LF; Abastado JP; Desprès P; Wang CI; Nardin A
    J Immunol; 2011 Mar; 186(5):3258-64. PubMed ID: 21278338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
    Kumar M; Sudeep AB; Arankalle VA
    Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Functional Determinants in the Chikungunya Virus E2 Protein.
    Weber C; Berberich E; von Rhein C; Henß L; Hildt E; Schnierle BS
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005318. PubMed ID: 28114368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
    Chen GL; Coates EE; Plummer SH; Carter CA; Berkowitz N; Conan-Cibotti M; Cox JH; Beck A; O'Callahan M; Andrews C; Gordon IJ; Larkin B; Lampley R; Kaltovich F; Gall J; Carlton K; Mendy J; Haney D; May J; Bray A; Bailer RT; Dowd KA; Brockett B; Gordon D; Koup RA; Schwartz R; Mascola JR; Graham BS; Pierson TC; Donastorg Y; Rosario N; Pape JW; Hoen B; Cabié A; Diaz C; Ledgerwood JE;
    JAMA; 2020 Apr; 323(14):1369-1377. PubMed ID: 32286643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.
    Lee CY; Kam YW; Fric J; Malleret B; Koh EG; Prakash C; Huang W; Lee WW; Lin C; Lin RT; Renia L; Wang CI; Ng LF; Warter L
    PLoS Pathog; 2011 Dec; 7(12):e1002390. PubMed ID: 22144891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
    Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
    MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
    Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
    Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand.
    Nitatpattana N; Kanjanopas K; Yoksan S; Satimai W; Vongba N; Langdatsuwan S; Nakgoi K; Ratchakum S; Wauquier N; Souris M; Auewarakul P; Gonzalez JP
    Virol J; 2014 Oct; 11():183. PubMed ID: 25330992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pseudotyped Viruses for the Alphavirus Chikungunya Virus.
    Wu J; Huang W; Wang Y
    Adv Exp Med Biol; 2023; 1407():299-312. PubMed ID: 36920704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates.
    Rossi SL; Comer JE; Wang E; Azar SR; Lawrence WS; Plante JA; Ramsauer K; Schrauf S; Weaver SC
    J Infect Dis; 2019 Jul; 220(5):735-742. PubMed ID: 31053842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.